1. FRI0216 Results of a longitudinal review of pulmonary function and safety data in a phase iib clinical programme testing granulocyte-macrophage colony-stimulating factor (GM–CSF) receptor antagonist mavrilimumab for treatment of rheumatoid arthritis (RA). (15th June 2017) Authors: Burmester, G; Michaels, MA; Close, D; Godwood, A; Middleton, K; Miranda, P; Vencovský, J; Kremer, J; McInnes, IB; Albulescu^, M; Weinblatt^, M Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗